Australia's Mayne Pharma set to snap 4-session skid on pushing ahead with Cosette scheme
View all comments(0)
Mayne Pharma Group MYX.AX rises 3.4% to A$4.63; set for steepest intraday pct gain since May 23
Stock on track to snap four consecutive sessions of losses
Co says U.S.-based Cosette's notice to scrap A$672 mln ($436.8 mln) deal not effective
Unanimously recommends shareholders to vote in favour of Cosette scheme
Adds it intends to proceed with the scheme meeting on June 18
More than 1.3 mln shares traded vs 30-day avg of 1.2 mln
MYX falls 9.7% this year, as of last close
($1 = A$1.5385)
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey





Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.